Ensartinib Lowers Recurrence Risk in ALK-Positive NSCLC

A marked separation in disease-free survival

In a peer-reviewed randomized phase 3 trial, adjuvant ensartinib reduced the risk of a disease-free survival event compared with the control strategy in patients with completely resected stage IB-IIIB non-small cell lung cancer harboring an anaplastic lymphoma kinase, or ALK, alteration. Participants had received postoperative chemotherapy before beginning daily targeted therapy.

Disease-free survival measures the time until recurrence, a new primary cancer or death, according to the protocol’s endpoint definition. It is clinically important in resected lung cancer because distant relapse, including relapse in the central nervous system, can be difficult to treat. It is not interchangeable with overall survival, however, and a large disease-free survival advantage does not by itself establish that patients live longer.

The magnitude of separation reported in the ensartinib study is the central finding. It suggests that residual ALK-driven tumor cells remain susceptible to kinase inhibition after surgery and chemotherapy, when disease is not radiographically detectable. A randomized design supports a causal interpretation of the treatment effect within the studied population, subject to protocol adherence, censoring assumptions and the maturity of follow-up.

The publication should be consulted directly for the participant count, hazard ratio, confidence interval, arm-level event totals, follow-up duration and adverse-event estimates. Those numerical details were not independently available in the source material provided for this draft and should not be reconstructed from secondary reporting.

How the postoperative strategy was tested

The study enrolled patients with stage IB-IIIB ALK-positive NSCLC whose tumors had been completely resected. Ensartinib was given once daily after chemotherapy and compared with the trial’s control strategy. The phase 3 design was intended to determine whether continued ALK inhibition could delay or prevent recurrence after local and cytotoxic treatment had been completed.

Several elements matter when interpreting the result. Complete resection defines a population treated with curative intent, rather than patients receiving systemic therapy for known residual or metastatic disease. Requiring ALK-positive disease makes the intervention biomarker selected. Administering ensartinib after chemotherapy also means the finding addresses sequential treatment, not replacement of indicated perioperative chemotherapy.

The breadth of stages is notable. Recurrence risk varies substantially from stage IB to stage IIIB, as do nodal burden, surgical selection and the likelihood of occult metastatic disease. The overall result therefore needs to be read alongside prespecified stage, nodal-status and other subgroup analyses. Such analyses can assess consistency, but they are often underpowered to establish that one subgroup benefits more or less than another.

Treatment duration is another practical variable. Adjuvant kinase inhibitors suppress susceptible clones while therapy continues, but the optimal duration is not established simply by showing that a protocol-defined course improves disease-free survival. Longer exposure may improve disease control, increase cumulative toxicity, or merely postpone recurrence in some patients. Follow-up after treatment ends is essential to distinguish these possibilities.

What the evidence changes in practice

The study adds to evidence that postoperative management of ALK-positive NSCLC should be considered separately from management of oncogene-negative disease. Surgery and chemotherapy address visible and microscopic disease broadly; an ALK inhibitor adds sustained pressure against tumor cells dependent on the molecular driver. That biological rationale now has support from more than one phase 3 adjuvant program.

The ALINA trial established an important benchmark. In that study, 257 patients with completely resected ALK-positive NSCLC were randomly assigned to alectinib or platinum-based chemotherapy. Among patients with stage II-IIIA disease, the hazard ratio for recurrence or death was 0.24, with a 95% confidence interval of 0.13 to 0.45. Two-year disease-free survival was 93.8% with alectinib and 63.0% with chemotherapy.

Alectinib also improved central nervous system disease-free survival.

The FDA subsequently approved alectinib for adjuvant treatment after tumor resection in adults with ALK-positive NSCLC meeting the agency’s tumor-size or node-positive criteria. That approval provides relevant US context, but it does not make ensartinib interchangeable with alectinib. Cross-trial comparisons are unreliable because eligibility, staging, prior chemotherapy, control groups, follow-up and endpoint assessment may differ.

For clinicians and health systems, the ensartinib result reinforces the need to identify ALK alterations early enough to inform postoperative planning. Molecular testing performed only after metastatic recurrence misses the opportunity to consider approved or investigational biomarker-directed adjuvant treatment. Pathology workflows must also preserve adequate tissue and return results without delaying other indicated care.

The finding does not establish an instruction for every patient with resected ALK-positive disease. Decisions depend on pathologic stage, resection margins, nodal involvement, prior treatment, comorbidities, competing recurrence risks, expected toxicity and access. In the United States, use should additionally be distinguished between an FDA-approved indication and an off-label or trial-based strategy.

Important uncertainties remain

Overall survival is the most consequential unresolved endpoint. Effective therapies available at recurrence can dilute or delay an overall survival difference, so long follow-up may be required. Even so, mature survival data are necessary to determine whether preventing or postponing recurrence translates into longer life rather than primarily shifting the timing of relapse.

Safety also needs full consideration. A prolonged adjuvant treatment exposes people without detectable cancer—including some already cured by surgery and chemotherapy—to adverse effects. The relevant balance includes treatment discontinuations, dose modifications, serious toxicities, liver and pulmonary effects, neurologic symptoms, cardiovascular findings, patient-reported outcomes and the reversibility of harms after therapy stops.

Generalizability may be limited by the trial’s geographic setting, surgical selection, ALK-testing methods and the proportion of patients represented in each stage. Stage IIIB disease is especially heterogeneous, and only carefully selected patients undergo complete resection. Results from that group should not be extended automatically to unresectable stage III disease or to patients with positive margins.

Funding and investigator conflicts should be reviewed in the full publication because industry involvement is common in registration-oriented oncology trials. Randomization reduces many forms of bias, but it does not eliminate concerns related to endpoint adjudication, missing assessments, informative censoring or selective emphasis on immature outcomes.

Questions clinicians ask

Does ensartinib replace postoperative chemotherapy?

No. The reported strategy used daily ensartinib after chemotherapy in patients whose ALK-positive tumors had been completely resected. The evidence therefore supports sequential targeted therapy in the studied setting; it does not show that ensartinib can substitute for chemotherapy when chemotherapy would otherwise be indicated.

Is disease-free survival enough to change care?

A large randomized disease-free survival benefit is clinically meaningful because recurrence can cause substantial morbidity and may be incurable. Still, clinicians should assess endpoint definition, follow-up, toxicity and central nervous system outcomes, while recognizing that the effect on overall survival remains a separate question.

Can these findings be applied to unresectable stage III disease?

No direct inference is justified. The trial concerned completely resected stage IB-IIIB disease treated with postoperative chemotherapy. Unresectable stage III NSCLC has different local therapy, systemic treatment and recurrence patterns, so management should be based on evidence generated for that setting.

Is ensartinib equivalent to adjuvant alectinib?

That has not been demonstrated. Both drugs inhibit ALK, but no head-to-head adjuvant trial establishes equivalent efficacy, safety or central nervous system protection. Regulatory status and the details of each trial should guide interpretation rather than an indirect comparison of disease-free survival results.

References

1. Ensartinib adjuvant therapy improves disease-free survival in resected ALK-positive NSCLC — PubMed, 2026
2. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer — The New England Journal of Medicine, 2024
3. FDA Approves Alectinib as Adjuvant Treatment for ALK-Positive Non-Small Cell Lung Cancer — US Food and Drug Administration, 2024